Table 1

Patient characteristics

VariableBaseline (N=133)Follow-upP value
Age (years)33 (26–43)N/A
Female sex, n (%)97 (73)N/A
WHO-FC (Ⅰ/Ⅱ/III/IV), n3/17/89/2410/86/35/2<0.001
6-MWD (m)375±120454±102<0.001
BNP (pg/mL)180 (55–446)40 (14–162)<0.001
Mean RAP (mm Hg)5 (3–8)4 (3–7)0.155
Mean PAWP (mm Hg)6 (4–8)6 (5–9)0.01
Mean PAP (mm Hg)56±1448±16<0.001
SvO2 (%)62±1067±9<0.001
Cardiac index (L/min/m2)1.80 (1.58–2.39)2.51 (1.94–3.18)<0.001
SVI (mL/m2)26.8 (18.8–34.3)35.5 (25.7–46.1)<0.001
PVR (WU)17.0 (11.7–23.9)10.6 (5.8–17.7)<0.001
ERS/ESC risk score, n (%)<0.001
 Low risk25 (19)73 (55)
 Intermediate risk86 (65)57 (43)
 High risk22 (17)3 (2)
Medication
 ERA, n (%)53 (40)N/A
 PDE-5i, n (%)40 (30)N/A
 Riociguat, n (%)4 (3)N/A
 Epoprostenol, n (%)70 (53)N/A
 Epoprostenol dose (ng/kg/min)21 (12–30)N/A
 Selexipag, n (%)1 (1)N/A
 CCB, n (%)6 (5)N/A
 Double therapy, n (%)12 (9)N/A
 Triple therapy, n (%)36 (27)N/A
  • Values are presented as mean±SD, median (IQR) or n (%).

  • BNP, B-type natriuretic peptide; CCB, calcium channel blocker; ERA, endothelin receptor antagonist; ERS, European Respiratory Society; ESC, European Society of Cardiology; 6-MWD, 6 min walk distance; N/A, not applicable; PAP, mean pulmonary artery pressure; PAWP, pulmonary arterial wedge pressure; PDE-5i, phosphodiesterase type five inhibitor; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SVI, stroke volume index; SvO2, mixed venous oxygen saturation; WHO-FC, WHO functional class; WU, Wood unit.